97 related articles for article (PubMed ID: 21545903)
1. Immunophenotyping of thyroid tumors identifies molecular markers altered during transformation of differentiated into anaplastic carcinoma.
Wiseman SM; Griffith OL; Gown A; Walker B; Jones SJ
Am J Surg; 2011 May; 201(5):580-6. PubMed ID: 21545903
[TBL] [Abstract][Full Text] [Related]
2. Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma.
Wiseman SM; Masoudi H; Niblock P; Turbin D; Rajput A; Hay J; Filipenko D; Huntsman D; Gilks B
Am J Surg; 2006 May; 191(5):581-7. PubMed ID: 16647341
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of transcription elogation factor A (SII) like 4 (TCEAL4) in anaplastic thyroid cancer.
Akaishi J; Onda M; Okamoto J; Miyamoto S; Nagahama M; Ito K; Yoshida A; Shimizu K
BMC Cancer; 2006 Nov; 6():260. PubMed ID: 17076909
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and prognostic role of HBME-1, galectin-3, and β-catenin in poorly differentiated and anaplastic thyroid carcinomas.
Rossi ED; Straccia P; Palumbo M; Stigliano E; Revelli L; Lombardi CP; Santeusanio G; Pontecorvi A; Fadda G
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):237-41. PubMed ID: 23235344
[TBL] [Abstract][Full Text] [Related]
5. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment.
Wiseman SM; Masoudi H; Niblock P; Turbin D; Rajput A; Hay J; Bugis S; Filipenko D; Huntsman D; Gilks B
Ann Surg Oncol; 2007 Feb; 14(2):719-29. PubMed ID: 17115102
[TBL] [Abstract][Full Text] [Related]
6. Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information.
Montero-Conde C; Martín-Campos JM; Lerma E; Gimenez G; Martínez-Guitarte JL; Combalía N; Montaner D; Matías-Guiu X; Dopazo J; de Leiva A; Robledo M; Mauricio D
Oncogene; 2008 Mar; 27(11):1554-61. PubMed ID: 17873908
[TBL] [Abstract][Full Text] [Related]
7. Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma.
Schwertheim S; Sheu SY; Worm K; Grabellus F; Schmid KW
Horm Metab Res; 2009 Jun; 41(6):475-81. PubMed ID: 19370508
[TBL] [Abstract][Full Text] [Related]
8. Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma.
Wiseman SM; Griffith OL; Deen S; Rajput A; Masoudi H; Gilks B; Goldstein L; Gown A; Jones SJ
Arch Surg; 2007 Aug; 142(8):717-27; discussion 727-9. PubMed ID: 17709725
[TBL] [Abstract][Full Text] [Related]
9. Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis.
Wiseman SM; Melck A; Masoudi H; Ghaidi F; Goldstein L; Gown A; Jones SJ; Griffith OL
Ann Surg Oncol; 2008 Oct; 15(10):2811-26. PubMed ID: 18612701
[TBL] [Abstract][Full Text] [Related]
10. [Anaplastic carcinoma of the thyroid at the Instituto Nacional de la Nutrición Salvador Zubirán].
Sierra M; Gamboa-Domínguez A; Herrera MF; Barredo-Prieto B; Alvarado de la Barrera C; Llorente L; Pérez-Enriquez B; Rivera R; González O; Rull JA
Rev Invest Clin; 1997; 49(2):97-103. PubMed ID: 9380971
[TBL] [Abstract][Full Text] [Related]
11. Quantitative measurement of telomerase reverse transcriptase, thyroglobulin and thyroid transcription factor 1 mRNAs in anaplastic thyroid carcinoma tissues and cell lines.
Takano T; Ito Y; Matsuzuka F; Miya A; Kobayashi K; Yoshida H; Miyauchi A
Oncol Rep; 2007 Sep; 18(3):715-20. PubMed ID: 17671725
[TBL] [Abstract][Full Text] [Related]
12. Anaplastic thyroid cancer: cytogenetic patterns by comparative genomic hybridization.
Miura D; Wada N; Chin K; Magrane GG; Wong M; Duh QY; Clark OH
Thyroid; 2003 Mar; 13(3):283-90. PubMed ID: 12729478
[TBL] [Abstract][Full Text] [Related]
13. Expression and mutation analysis of the tyrosine kinase c-kit in poorly differentiated and anaplastic thyroid carcinoma.
Broecker-Preuss M; Sheu SY; Worm K; Feldkamp J; Witte J; Scherbaum WA; Mann K; Schmid KW; Schott M
Horm Metab Res; 2008 Oct; 40(10):685-91. PubMed ID: 18622894
[TBL] [Abstract][Full Text] [Related]
14. Expression of oncofetal fibronectin mRNA in thyroid anaplastic carcinoma.
Takano T; Ito Y; Matsuzuka F; Miya A; Kobayashi K; Yoshida H; Miyauchi A
Jpn J Clin Oncol; 2007 Sep; 37(9):647-51. PubMed ID: 17704536
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of the mitotic spindle assembly checkpoint genes hBUB1, hBUBR1 and hMAD2 in thyroid carcinomas with aggressive nature.
Wada N; Yoshida A; Miyagi Y; Yamamoto T; Nakayama H; Suganuma N; Matsuzu K; Masudo K; Hirakawa S; Rino Y; Masuda M; Imada T
Anticancer Res; 2008; 28(1A):139-44. PubMed ID: 18383837
[TBL] [Abstract][Full Text] [Related]
16. Biological significance of aminopeptidase N/CD13 in thyroid carcinomas.
Kehlen A; Lendeckel U; Dralle H; Langner J; Hoang-Vu C
Cancer Res; 2003 Dec; 63(23):8500-6. PubMed ID: 14679016
[TBL] [Abstract][Full Text] [Related]
17. Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification.
Elliott DD; Sherman SI; Busaidy NL; Williams MD; Santarpia L; Clayman GL; El-Naggar AK
Hum Pathol; 2008 Jan; 39(1):15-20. PubMed ID: 17949783
[TBL] [Abstract][Full Text] [Related]
18. FOXA1 is a potential oncogene in anaplastic thyroid carcinoma.
Nucera C; Eeckhoute J; Finn S; Carroll JS; Ligon AH; Priolo C; Fadda G; Toner M; Sheils O; Attard M; Pontecorvi A; Nose V; Loda M; Brown M
Clin Cancer Res; 2009 Jun; 15(11):3680-9. PubMed ID: 19470727
[TBL] [Abstract][Full Text] [Related]
19. Genetic mutations in thyroid carcinoma.
Taccaliti A; Boscaro M
Minerva Endocrinol; 2009 Mar; 34(1):11-28. PubMed ID: 19209125
[TBL] [Abstract][Full Text] [Related]
20. Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy.
Wiseman SM; Loree TR; Rigual NR; Hicks WL; Douglas WG; Anderson GR; Stoler DL
Head Neck; 2003 Aug; 25(8):662-70. PubMed ID: 12884350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
